ms

For December 2015 we have selected: Ramanujam R, Hedstrom A-K, Manouchehrinia A, et al. Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol 2015; 72(10):1117-1123. The usual course of multiple sclerosis (MS) is characterized by the conversion to secondary progressive disease within about 20 years from the first attack. Great efforts are currently made to modify the disease progression with the use of aggressive and expensive medical treatments.

Gian Luigi Lenzi (GLL): As Member at Large to the EAN, can you illustrate the role you give to EAN within the community of European Neurologists? Per Soelberg Sorensen (PSS): As member at Large to the EAN I am proud to be a part of this new important amalgamation of ENS and EFNS. It is the aim of the new board to develop EAN into a European organisation that can match the American Academy of Neurology in worldwide importance.

The Patient Day – organised in cooperation with the Turkisch Neurological Society, EFNS/ ENS and EFNA in Hamidiye Hall at the ICC, Saturday, 2014-05-31 8.30-10.30 The aspects of the relationship between patients and physicians are changing due to the knowledge… Continue Reading

Although there are myriad new treatment options for multiple sclerosis, this disease is still hard to get under control. Experts at the Congress of the European Neurological Society in Barcelona urged massive efforts to be made in pharmacogenetics so that… Continue Reading

by Gian Luigi Lenzi The first year, NEUROPENEWS, published every month the abstract of one of the scientific publications from the year 2009 that received the largest number of quotations during 2011. This interval of at least a year between… Continue Reading

by Michael Khalil Multiple Sclerosis (MS) is a main area of interest for Austria’s neurologic community. One reason for this is the rather high prevalence of this disorder which in 2002 has been estimated to be around 100 per 100,000… Continue Reading

Polman, CH.; Reingold, SC; Banwell, B; et al. ANNALS OF NEUROLOGY Volume: 69 Issue: 2 Pages: 292-302 Published: FEB 2011 Abstract:
New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis. The… Continue Reading

Abstract: Objective: To report the results of a 24-month extension of a phase II trial assessing the efficacy, safety, and tolerability of the once-daily oral sphingosine-1-phosphate receptor modulator, fingolimod (FTY720), in relapsing multiple sclerosis (MS).
Methods: In the randomized, double-blind,… Continue Reading

In April 2011, the EFNS together with ENS and ECTRIMS, have published this important statement. What is the follow-up?
https://www.efns.org/uploads/media/CCSVI_in_MS_ECTRIMS_EFNS_ENS_02.pdf Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis – From “The Big Idea” to “The Perfect Crime”? By Christos Krogias,… Continue Reading

In the last six months, the EFNS Scientific Fellowship programme gave me the opportunity to work as visiting scientist in the Laboratory for Molecular Neurology, coordinated by Prof. Dr. Orhan Aktas, at the Department of Neurology of the Heinrich-Heine University, Düsseldorf, Germany, chaired by Prof. Dr. Hans-Peter Hartung.